Search filters

Filters
Clear All

Phase

  • 59
  • 97
  • 108
  • 90
  • 14
  • 168
  • 694
  • 444
  • 14
  • 31
  • 1
  • 4
  • 646

Found 696 none trials

A listing of none medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)  A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
99 years or below
All genders
Phase 3
The purpose of this study is to find if adding the study drug, nivolumab (also known as OPVIDO), will limit lung cancer from growing back in patients with early stage non-small cell lung cancer. Nivolumab is a drug that may turn on the body's immune system to attack any cancer …
 ADP-0000-002: Long Term Follow-up of Subjects Exposed to NY-ESO-1c259 T  A Genetically Engineered NY-ESO-1 Specific T Cell Receptor
99 years or below
All genders
This non-therapeutic, multi-center LTFU study involves up to 15 years post-infusion monitoring of subjects who have been exposed to lentivirus-mediated gene transfer in Adaptimmune clinical studies. Subjects will undergo clinical evaluation with careful attention to adverse events possibly related to gene transfer/lentivirus-induced diseases. Blood samples will be collected. Subjects will …
 UPCC 04717: Phase I  open label  dose-escalation study to evaluate the safety  expansion  persistence of a single dose of UCART19 (allogeneic engineered T-cells expressing anti-CD19 chimeric antigen receptor)  administered intravenously in patients with relapsed or refractory CD19 positive B-cell acute lymphoblastic leukaemia (B-ALL)
99 years or below
All genders
Phase 1
The main aims of this study are to test the safety of up to 4 different doses of UCART19, and to identify the best dose of UCART19, by measuring what has happened to the leukemia cells at day 28 (28 days after the administration of UCART19), day 84 (84 days …
 UPCC 16517: A Phase 1  First-in-Human  Open-Label  Dose Escalation Study of JNJ-61186372  a Human Bispecific EGFR and cMet Antibody  in Subjects with Advanced Non-Small Cell Lung Cancer
99 years or below
All genders
Phase 1
The purpose of this study is to see if JNJ-61186372 is safe and useful for treating patients with advanced, metastatic, non-small cell lung cancer (NSCLC).
 UPCC 06717 / AMC 101: A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas
18 years - 64 years
All genders
Phase 1
Non-Hodgkin lymphoma  is a potentially curable condition with standard cancer treatment drugs (chemotherapy) and steroids. Standard lymphoma treatment includes chemotherapy, or cancer-fighting drugs, called etoposide, vincristine, cyclophosphamide, prednisone and doxorubicin (called EPOCH).  
 Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) Protocol
40 years - 64 years
All genders
The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment . Clinical/cognitive, imaging, biomarker, and genetic characteristics will be assessed across three cohorts: (1) early onset Alzheimer's Disease (EOAD) participants, (2) early onset …
461 - 470 of 696